CDKN2A deletions are associated with poor outcomes in 101 adults with T‐cell acute lymphoblastic leukemia. Issue 3 (24th December 2020)

• Record Type: Journal Article
• Authors: Wang, Huan‐Ping; Zhou, Yi‐Le; Huang, Xin; Zhang, Yi; Qian, Jie‐Jing; Li, Jian‐Hu; Li, Xue‐Ying; Li, Chen‐Ying; Lou, Yin‐Jun; Mai, Wen‐Yuan; Meng, Hai‐Tao; Yu, Wen‐Juan; Tong, Hong‐Yan; Jin, Jie; Zhu, Hong‐Hu
• Is Part Of: American journal of hematology. Volume 96:Issue 3(2021)
• Page Start: 312
• Page End: 319
• Publication Date: 2020-12-24
• Subjects: Hematology -- Periodicals; 616.15
• DOI: 10.1002/ajh.26069
• Languages: English
• ISSNs: 0361-8609

Abstract

Abstract: The identification of genetic risk subgroups of T‐cell acute lymphoblastic leukemia (T‐ALL) may provide evidence for risk stratification and individualized treatment. We investigated the characteristics and prognostic value of tumor suppressor gene CDKN2A deletions in 101 patients with T‐ALL. The CDKN2A deletion was present in 23% (23/101) of T‐ALL by fluorescence in situ hybridization (FISH). The most common type of CDKN2A deletion was homozygous deletion (70%, 16/23). A lower frequency of CDKN2A deletion was found in patients with early T‐cell precursor (ETP) ALL than in patients with non‐ETP‐ALL (10.4% vs 34.0%; P = .008). Deletion of CDKN2A was significantly associated with younger age ( P = .001), higher white blood cell (WBC) count ( P < .001) and higher lactate dehydrogenase (LDH) level ( P = .002). Patients with CDKN2A deletion had lower 2‐year overall survival (OS) and event‐free survival (EFS) rates than patients without CDKN2A deletion (2‐year OS: 18.6% ± 8.9% vs 47.4% ± 6.2%, P = .032; EFS: 16.4 ± 8.3 vs 38.6 ± 5.9%, P = .022). In multivariable analysis, CDKN2A deletion was an independent adverse prognostic factor for OS ( P = .016). In conclusion, adult T‐ALL patients with CDKN2A deletion had a poor prognosis, and these patients might benefit from intensive chemotherapy or allogeneic hematopoietic stem‐cell transplantation.